Brief: Cellect Biotechnology's Apograft To Empower Cellular Treatment Of Covid-19 Related Pulmonary Diseases

Quoin Pharmaceuticals

18/05/2020 13:17

May 18 (Reuters) - Cellect Biotechnology Ltd  APOP.O :
    * CELLECT BIOTECHNOLOGY'S APOGRAFT™ TO EMPOWER CELLULAR
TREATMENT
OF COVID-19 RELATED PULMONARY DISEASES
    * CELLECT BIOTECHNOLOGY - CLINICAL RESULTS IN GVHD STUDIES
MAY BE
BENEFICIAL IN COVID-19 AND CAR-T CYTOKINE STORM MANIFESTATIONS
    * CELLECT BIOTECHNOLOGY - SIGNED A DEVELOPMENT AGREEMENT
WITH
CONSORTIUM TO EXAMINE THERAPEUTIC EFFECTS OF APOGRAFT TREATED
STEM CELLS
    * CELLECT BIOTECHNOLOGY LTD - DEVELOPMENT AGREEMENT INCLUDES
A
COMMERCIAL COMPONENT
    * CELLECT BIOTECHNOLOGY LTD - DID NOT DISCLOSE TERMS OF
AGREEMENT,
NOR ANY MEMBERS OF INTERNATIONAL CONSORTIUM

Source text for Eikon:  ID:nPn9w1KgGa 
Further company coverage:  APOP.O 

 ((Reuters.Briefs@thomsonreuters.com;))